US Patent Issued to Taiho Pharmaceutical on March 18 for "Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer" (Japanese Inventor)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,251,447, issued on March 18, was assigned to Taiho Pharmaceutical Co. Ltd. (Tokyo).

"Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer" was invented by Yuki Tanaka (Ibaraki, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a novel cancer treatment method that exhibits a significantly excellent antitumor effect and causes less adverse reactions. The present invention provides an antitumor agent wherein a peptide having 4 linked epitopes and an immune checkpoint modulator are administered in combination. An antitumor effect in humans ca...